^{3rd International Conference on Cancer Biology & Anti-Cancer Therapies and Drug Development & Delivery} May 30-31, 2019 Orlando, Florida, USA

Andrei L. Gartel, PhD is an Associate Professor in the Departments of Medicine and Biochemistry & Molecular Genetics at the University of Illinois at Chicago. He is the author of more than 75 peer-review publications that include more than 15 reviews with more than 3000 citations. His scientific interests include the cancer, regulation of cell cycle, cyclin dependent kinase inhibitors, oncogenic transcription factors FOXM1 and c-Myc, and mechanisms of action of anticancer drugs. Recently his lab identified oncogenic transcription factor FOXM1, which is strongly overexpressed in a human cancer, as a novel major target for proteasome inhibitors. He received his funding from NIH, DOD and private companies/foundations. He is an academic editor of PLOS ONE.

Positive and negative regulation of oncogenic transcription factor FoxM1. Identification of novel anticancer drugs against human neoplasia

Dr. Luo has been studying molecular pathology related to human malignancies in the last 30 years. Currently, he is a Professor of Pathology and Director of High Throughput Genome Center at University of Pittsburgh. In the last 17 years, Dr. Luo has been largely focusing on the genetic and molecular mechanism of human prostate and hepatocellular carcinomas. In this period, his group has identified and characterized several genes that are related to prostate cancer and hepatocellular carcinoma, including SAPC, myopodin, CSR1, GPx3, ITGA7, MCM7, MCM8, MT1h and GPC3. He has characterized several signaling pathways that play critical role in prostate cancer development, including Myopodin-ILK-MCM7 inhibitory signaling, myopodin-zyxin motility inhibition pathway, CSR1-CPSF3, CSR1-SF3A3 and CSR1-XIAP apoptotic pathways, MT1h-EHMT1 epigenomic signaling, ITGA7-HtrA2 tumor suppression pathway, GPx3-PIG3 cell death pathway, AR-MCM7, MCM7-SF3B3 and MCM8-cyclin D1 oncogenic pathways. He proposed prostate cancer field effect in 2002. He is one of the pioneers in utilizing high throughput gene expression and genome analyses to analyze field effects in prostate cancer and liver cancer. He is also the first in using methylation array and whole genome methylation sequencing to analyze prostate cancer. Recently, his group discovered several novel fusion transcripts and their association with aggressive prostate cancer. One of the fusion genes called MAN2A1-FER, was found present in 6 different types of human cancers. He later defined a critical MAN2A1-FER/EGFR signaling pathway that is essential for MAN2A1-FER mediated transformation activity. His group also developed a genome intervention strategy targeting at the chromosomal breakpoint of fusion gene to treat cancers. Overall, these findings advance our understanding of how cancer develops and behaves, and lay down the foundation for better future diagnosis and treatment of human malignancies.

Dr. Luo has been largely focusing on the genetic and molecular mechanism of human prostate and hepatocellular carcinoma.

Dr./Prof. Yoshiaki Omura was born March 28, 1934 in Asahi-Machi, Toyoma Prefecture, Japan.　Married 1962, separated; 2 sons, 1 daughter. Became U.S. citizen 1979. Home: 800 Riverside Dr., Apt. 8-I, New York, N.Y. 10032-7416.Education:- 1952-54: Associate Degree in Electrical Engineering and Pre-Medicine, Nippon University, where he ranked among the top ten students in a class of nearly 400.- 1957 : earned Bachelor of　Science degree (M.S. equivalent in the U.S.A.) from Waseda University Department of Applied Physics, in Tokyo.- 1958 : M.D. degree at the School of Medicine, Yokohama City University, with both the Ikueikai Scholarship and a Special Medical Research Scholarship, given by the Ministry of Education of the Japanese Government to one medical student at each medical school each year to encourage and support outstanding student research.- One year Rotating Internship at the Tokyo University Hospital, working part-time in the evenings at the Emergency Hospital in Yokohama.- Two months of Residency with the Department of Surgery at Tokyo University Branch Hospital.- 1959 : Moved to U.S. : Twelve months Rotating Internship at Norwalk Hospital in Norwalk, Connecticut.- 1960-63 : Research fellow, cardiovascular surgery at Columbia University, New York City.

Chemotherapy, Cancer, Cardiology, Therapeutics

Professor Diana Anderson completed her PhD in the Faculty of Medicine, University of Manchester, UK. She currently holds the Established Chair in Biomedical Sciences at the University of Bradford. She has published over 450 papers and eight books. She has served on 10 editorial boards, has supervised 30 PhD students and is Editor- in- Chief of the Book Series “Issues in Toxicology” for the Royal Society of Chemistry. She has hosted and participated in 56 meetings for the WHO on Chemical Safety. She has been a Vice President of the Institute of Biology.

Her research interests mainly focuses on cancer, oxygen radicals, human biomonitoring, unbalanced precursor pools, dietary imbalance, male-mediated developmental defects, nanotoxicology, general toxicology